Actuate Therapeutics Inc
ACTUNASDAQHealthcareBiotechnology
Previous close
$1.27
+$0.04 · +3.25%
Pre-market
$1.27
$0.00 · 0.00%
Aug 24, 4:00 AM ET
ACTU company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
26
Expensive
Momentum
25
Weakening
Sentiment
41
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteActuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Daniel Schmitt
- Listed since
- Aug 13, 2024
- Employees
- 12
Market position
Day range
Current $1.27
52-week range
Current $1.27
- Open
- $1.22
- Previous close
- $1.23
- Volume
- 275.82K
- 1.09× average
- Average volume
- 252.35K
- Average daily volume
- Market cap
- 30.39M USD
- Beta
- 0.78
- Market reference 1
- 50-day average
- $1.4161
- -10.32% below average
- 200-day average
- $3.5414
- -64.14% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 115.9M USD
- P/E (TTM)
- -1.43×
- P/B (TTM)
- 30.65×
- P/S (TTM)
- 0×
- EV / EBITDA
- -5.22×
- Earnings yield
- -17.28%
- Free cash flow yield
- -14.93%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -280.51%
- Return on assets
- -158.36%
- Return on invested capital
- -270.08%
Financial health
- Debt / equity
- 0.41×
- Current ratio
- 2.39×
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$21.00
1553.54% upsideACTU peers
ETFs holding ACTU
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 319K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
Vanguard Extended Market ETFVXF- Market value
- 117.71K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Micro-Cap ETFIWC- Market value
- 47.64K
- Weight
- 0.00%
- AUM
- 1.53B USD
- Expense ratio
- 0.60%
- Price / 1D
- $198.39+1.10%
Continue in GoAI
Research ACTUresearch.disclaimer